Article Sidebar

PDF
Date Published: 27/10/2023
Abstract Views: 122
Views PDF: 95
DOI: https://doi.org/10.51298/vmj.v531i1.6911
Issue
Vol. 531 No. 1 (2023)
Section
Các bài báo
How to Cite
Đỗ , A. T. ., & Nguyễn , Đình L. . (2023). OVERALL SURVIVAL OUTCOME AND PROGNOSTIC FACTORS IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION – RESISTANT PROSTATE CANCER TREATED WITH ABIRATERONE ACETATE. Vietnam Medical Journal, 531(1). https://doi.org/10.51298/vmj.v531i1.6911

OVERALL SURVIVAL OUTCOME AND PROGNOSTIC FACTORS IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION – RESISTANT PROSTATE CANCER TREATED WITH ABIRATERONE ACETATE

Anh Tú Đỗ 1,, Đình Lợi Nguyễn 2
1 k hospital
2 HMU

Main Article Content

Abstract

Background: In real - life, metastatic castration – resistant prostate cancer patients (mCRPC) had more complex clinical presentation than patients in the COU - AA 302 trial. This study primarily aimed to describe overall survival of chemotherapy-naïve mCRPC treated with abiraterone acetate plus prednisone (AAP). Other relevant outcomes, baseline characteristics of these patients were also evaluated. Methods: This retrospective, observational study collected data from chemotherapy-naïve mCRPC patients treated with AAP in Vietnam National cancer hospital. Kaplan-Meier curves were used to estimate time to treatment failure (TTF), and overall survival (OS). The impact of baseline characteristics on OS was explored using univariate and multivariate Cox proportional hazard models. Results: Data from 65 eligible patients were analyzed. At AAP initiation, the median age of patients was 70 years (interquartile range [IQR]: 64–76). Patients had ECOG PS ≥ 2 was 24,6%, pain symptoms (BPS - SF > 3) was 36,9% and visceral metastases were 16,9%; exclusion criterion in the COU-AA-302 trial. The rate of PSA response was 73,8%, median PSA PFS was 10,5 months (95% CI: 7,4-13,6), median TTF was 15,0 months (95% CI: 11,1-18,9), and median OS was 24,9 months (95% CI: 18.9-30.9). Shorter OS was significantly associated with higher Gleason score (≥ 8), shorter the time from ADT start to AAP (<12 months), visceral metastases, and < 50% PSA decline (p < 0.05). Conclusion: Abiraterone acetate plus prednisone is well tolerated and effective for chemotherapy-naïve mCRPC patients in clinical practice.

Article Details

Keywords

Metastatic castration-resistant prostate cancer, abiraterone acetate, overall survival

References

1. Cancer today. , accessed: 05/08/2023.
2. Ryan C.J., Smith M.R., De Bono J.S. và cộng sự. (2013). Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med, 368(2), 138–148.
3. Boegemann M., Khaksar S., Bera G. và cộng sự. (2019). Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study. BMC Cancer, 19(1), 60.
4. Pilon D., Behl A.S., Ellis L.A. và cộng sự. (2017). Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. J Manag Care Spec Pharm, 23(2), 225–235.
5. Alvim C.M., Mansinho A., Paiva R.S. và cộng sự. Prognostic factors for patients treated with abiraterone. Future Sci OA, 6(2), FSO436.
6. Tseng C.-S., Yang J.-H., Huang S.-W. và cộng sự. (2023). Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer. BMC Cancer, 23, 568.
7. Sweeney C.J., Chen Y.-H., Carducci M. và cộng sự. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med, 373(8), 737–746.
8. Koura M., Shiota M., Ueda S. và cộng sự. (2021). Prognostic impact of prior local therapy in castration-resistant prostate cancer. Jpn J Clin Oncol, 51(7), 1142–1148.